Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans

Obesity Surgery

Volumn 27, Issue 7, 2017, Pages 1789-1796

  Biagioni, Maria Fernanda G ^a   Mendes, Adriana L ^a   Nogueira, Célia Regina ^a   Leite, Celso V ^a   Gollino, Loraine ^a   Mazeto, Gláucia Mfs ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bariatric surgery; Biomarkers; Bone remodeling; Cytokines; Wnt catenin LRPs

Indexed keywords

25 HYDROXYVITAMIN D; ADIPOCYTOKINE; ADIPONECTIN; ALKALINE PHOSPHATASE; BONE SPECIFIC ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; SOST PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN;

ADIPOCYTE; ADULT; ARTICLE; BARIATRIC SURGERY; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE REMODELING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FAT FREE MASS; FAT MASS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; OBSERVATIONAL STUDY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; ROUX-EN-Y GASTRIC BYPASS; WEIGHT REDUCTION; ANTHROPOMETRY; BIOSYNTHESIS; BLOOD; BODY WEIGHT LOSS; GASTRIC BYPASS SURGERY; GENETIC MARKER; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; YOUNG ADULT;

ADIPOCYTES; ADIPOKINES; ADULT; ANTHROPOMETRY; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; FEMALE; GASTRIC BYPASS; GENETIC MARKERS; HUMANS; MIDDLE AGED; OBESITY; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND; WEIGHT LOSS; YOUNG ADULT;

EID: 85010764379     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-017-2546-4     Document Type: Article

References (62)

1. World Health Organization. Global status report on non communicable diseases 2014. Disponível em:< http://www.who.int/nmh/publications/ncd-status-report-2014/en/>. Access in: mar. 2016.
2. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14(Suppl 1):1–83.
3. Ricci C, Gaeta M, Rausa E, et al. Early impact f bariatric surgery on type II diabetes, hipertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6.587 patients. Obes Surg. 2014;24:522–8.
4. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36.
5. Stemmer K, Bielohuby M, Grayson BE, et al. Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats. Endocrinology. 2013;154:2015–24.
6. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes. Consequences and Management Lancet Diabetes Endocrinol. 2014;2(2):165–74.
7. Yu EW, Bouxsein ML, Putman MS, et al. Two-year changes in bone density after Roux-en-Y gastric bypass surgery. J Clin Endocrinol Metab. 2015;100(4):1452–9.
8. Liu C, Wu D, Zhang J, et al. Changes in bone metabolism in morbidly obese patients after bariatric surgery: a meta-analysis. Obes Surg. 2016;26(1):91–7.
9. Yu EW. Bone metabolism after bariatric surgery. J Bone Miner Res. 2014;29(7):1507–18.
10. Karefylakis C, Näslund I, Edholm D, et al. Vitamin D status 10 years after primary gastric bypass: gravely high prevalence of hypovitaminosis D and raised PTH levels. Obes Surg. 2014;24(3):343–8.
11. Hage MP, El-Hajj FG. Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporosis Int. 2014;25:423–39.
12. Butte NF, Brandt ML, Wong WW, et al. Energetic adaptations persist after bariatric surgery in severely obese adolescents. Obesity (Silver Spring). 2015;23(3):591–601.
13. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblastos through the MAPK signalling pathway. J Bone Miner Res. 2006;21:1648–56.
14. Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-ΚB ligand derived from osteoblasts. J Immunol. 2007;178:192–200.
15. Elissondo N, Rosso LG, Maidana P, et al. Adiponectina: una adipocitoquina con múltiples funciones protectoras. Acta Bioquím Clín Latinoam. 2008;42(1):17–33.
16. Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res. 2011;6:30.
17. Kanazawa I. Adiponectin in metabolic bone disease. Curr Med Chem. 2012;19(32):5481–92.
18. Hogan SL. The effects of weight loss on calcium and bone. Crit Care Nurs Q. 2005;28(3):269–75.
19. Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97(5):1655–62.
20. Muschitz C, Kocijan R, Marterer C, et al. Sclerostin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab. 2015;100(3):891–901.
21. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.
22. Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26:1425–36.
23. Moester MJC, Papapoulos SE, Löwik CWGM, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87(2):99–107.
24. Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med. 2011;12(65):263–73.
25. Dovjak P, Dorfer S, Föger-Samwald U, et al. Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014;60:493–501.
26. Eriksen EF. Commentary on sclerostin deficiency is linked to altered bone composition. J Bone Miner Res. 2014;29(10):2141–3.
27. Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93(10):3735–40.
28. Gannagé-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158(3):353–9.
29. Wroblewski E, Swidnicka-Siergiejko A, Hady HR, et al. Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies. Cytokine. 2016;77:56–62.
30. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocr Pract. 2013;19(2):337–72.
31. Viégas M, Vasconcelos RS, Neves AP, et al. Bariatric surgery and bone metabolism: a systematic review. Arq Bras Endocrinol Metabol. 2010;54(2):158–63.
32. Vasconcelos RS, Viégas M, Marques TF, et al. Factors associated with secondary hyperparathyroidism in premenopausal women undergoing Roux-en-Y gastric bypass for the treatment of obesity. Arq Bras Endocrinol Metabol. 2010;54(2):233–8.
33. Williams SE. Metabolic bone disease in the bariatric surgery patient. J Obes. 2011;2011:634614.
34. Carrasco F, Basfi-fer K, Rpjas P, et al. Changes in bone mineral density after sleeve gastrectomy or gastric bypass: relationships with variations in vitamin D, ghrelin, and adiponectin levels. Obes Surg. 2014;24:877–84.
35. Register TC, Divers J, Bowden DW, et al. Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2013 May;98(5):1916–22.
36. Balsa JA, Lafuente C, Gómez-Martín JM, et al. The role of serum osteoprotegerin and receptor–activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery. J Bone Miner Metab. 2015;1-7
37. Elias E, Casselbrant A, Werling M, et al. Bone mineral density and expression of vitamin D receptor-dependent calcium uptake mechanisms in the proximal small intestine after bariatric surgery. Br J Surg. 2014;101(12):1566–75. doi:10.1002/bjs.9626.
38. Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab. 2010;95(1):159–66. doi:10.1210/jc.2009-0265.
39. Biagioni MFG, Mendes AL, Nogueira CR, et al. Weight-reducing gastroplasty with Roux-en-Y gastric bypass: impact on vitamin D status and bone remodeling markers. Metab Syndr Relat Disord. 2014;12(1):11–5.
40. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331(2):520–6.
41. Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33(4):646–51.
42. Aguirre L, Napoli N, Waters D, et al. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. J Clin Endocrinol Metab. 2014;99(9):3290–7.
43. Naot D, Cornish J. Cytokines and hormones that contribute to the positive association between fat and bone. Front Endocrinol. 2014;5:70.
44. Carrasco F, Ruz M, Rojas P, et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg. 2009;19(1):41–6.
45. Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab. 2010;95:159–66.
46. Prado WL, Piano A, Lazaretti-Castro M, et al. Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolescents. J Bone Miner Metab. 2009;27:613–9.
47. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17:1563–9.
48. Walicka M, Czerwińska E, Tałałaj M, et al. Influence of weight reduction on leptin concentration and bone mineral density in patients with morbid obesity before and 6 months after bariatric surgery. Endokrynologia Polska. 2009;60(2):97–102.
49. Mohiti-Ardekani J, Soleymani-Salehabadi H, et al. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. 2014;32(4):400–4.
50. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42(4):606–15.
51. Zhang R, Oyajobi BO, Harris SE, et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone. 2013;52(1):145–56.
52. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.
53. Wang Y, Lam KS, Xu JY, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280:18341–7.
54. Schoenau E. Bone mass increase in puberty: what makes it happen? Horm Res Paediatr. 2006;65(2):2–10.
55. Frost HM. Bone “mass” and the “mechanostat”. A proposal Anat Rec. 1987;219:1–9.
56. Van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22(1):19–28.
57. Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619–27.
58. Bellido T. Summary—osteocyte control of bone formation via Sost/sclerostin. J Musculoskelet Neuronal Interact. 2006;6(4):360–3.
59. Granado-Lorencio F, Simal-Antón A, Salazar-Mosteiro J, et al. Time-course changes in bone turnover markers and fat-soluble vitamins after obesity surgery. Obes Surg. 2010;20:1524–9.
60. Villareal RA, Sadler C, Napoli N, et al. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. Bone Miner Res. 2012;27(5):1215–21.
61. Muschitz C, Kocijan R, Haschka J, et al. The impact of vitamin D, calcium, protein supplementation, and physical exercise on bone metabolism after bariatric surgery: the BABS study. J Bone Miner Res. 2016;31(3):672–82.
62. Deitel M, Greenstein R. Editorial: recommendations for reporting weight loss. Obes Surg. 2003;13:159–60.